Pro-Dex, Inc.
NASDAQ:PDEXMedical - Instruments & Supplies
+$3.54 today
- Market cap
- $204.61M
- Beta
- -0.00
- P/E (TTM)
- 17.1
- EPS (TTM)
- $3.75
Volume 0.04M
Average 0.04M
PDEX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Pro-Dex, Inc.NASDAQ: PDEX
EBITDA · Q3 FY2026 · quarter ended Mar 2026
EBITDA grows, but more slowly than its trailing trend
Q3 FY2026 EBITDA of $5.9M rose 27.8% year over year, behind the +41.4% change in trailing-twelve-month EBITDA. Sequentially, it rose 74.5% from the prior quarter. Over 3 fiscal years it compounded at +27.1% a year.
Context
- EBITDA amounted to 21.2% of revenue in FY2025, up 13.1 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 1 analysts of $19.12M (+35.3%) for the fiscal year ending Jun 2026, a slowdown from the +224.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.9M+74.5% QoQ
- Last fiscal yearJun 2025
- $14.13M+224.6% YoY
- LTMMar 2026
- $19.63M+41.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +27.8% | -1.6% | -29.5 pp |
| 1 year | +224.6% | +35.3% | -189.2 pp |
| 3-year CAGR | +27.1% | +6.7% | -20.4 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 14.13M USD
- Year-over-year change
- +224.6%
- 4-year CAGR
- +19.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 14.13M | +224.6% |
| FY2024 | 2024-06-30 | 4.35M | -59.8% |
| FY2023 | 2023-06-30 | 10.82M | +57.1% |
| FY2022 | 2022-06-30 | 6.88M | +0.0% |
| FY2021 | 2021-06-30 | 6.88M | — |
EBITDA vs competitors
How PDEX compares with its peers on the latest reported figures
- PDEX's LTM Mar 2026 EBITDA of $19.63M is the highest of the 9 companies compared; the peer median is -$26.49M.
- Its year-over-year change of +41.4% is the 3rd highest of 9, against a peer median of -2.9%.
- EBITDA amounts to 26.3% of revenue for PDEX, versus a peer median of 7176.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $19.63M | +41.4% | +27.1% | 26.3% | |
| LTM Mar 2026 | -$2.44M | +81.8% | — | 4.4% | |
| LTM Mar 2026 | -$14.17M | -22.2% | — | 13493.3% | |
| LTM Mar 2026 | -$19.31M | +41.5% | — | — | |
| LTM Mar 2026 | -$21.76M | -35.5% | — | — | |
| LTM Mar 2026 | -$31.22M | +2.8% | — | 54764.9% | |
| LTM Mar 2026 | -$44.12M | +27.6% | — | 859.3% | |
| LTM Mar 2026 | -$45.12M | -8.6% | — | 131.2% | |
| LTM Mar 2026 | -$341.95M | -5893.3% | — | 86155.0% | |
| Peer median (excluding PDEX) | -$26.49M | -2.9% | — | 7176.3% | |
Competitors are the stored peer set for PDEX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Jun 2021 | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 42.04M | 42.04M | 46.09M | 53.84M | 66.59M |
| Cost of Revenue | 28.91M | 28.91M | 33.34M | 39.29M | 47.08M |
| Gross Profit | 13.13M | 13.13M | 12.75M | 14.55M | 19.51M |
| Gross Margin | 31.2% | 31.2% | 27.7% | 27.0% | 29.3% |
| Research & Development | 2.98M | 2.98M | 2.8M | 3.19M | 3.64M |
| Selling, General & Admin | 4.99M | 4.99M | 4.18M | 4.19M | 5.19M |
| Operating Expenses | 8.01M | 8.01M | 6.99M | 7.38M | 8.82M |
| Depreciation & Amortization | 726K | 726K | 857K | 1.16M | 1.24M |
| EBITDA | 6.88M | 6.88M | 10.82M | 4.35M | 14.13M |
| EBITDA Margin | 16.4% | 16.4% | 23.5% | 8.1% | 21.2% |
| Operating Income | 5.12M | 5.12M | 5.76M | 7.17M | 10.69M |
| Operating Margin | 12.2% | 12.2% | 12.5% | 13.3% | 16.1% |
| Interest Income | 126K | 76K | 294K | 144K | 82K |
| Interest Expense | 352K | 464K | 533K | 558K | 829K |
| Other Income / Expenses | 571K | 571K | 3.67M | (4.54M) | 1.37M |
| Income Before Tax | 5.69M | 5.69M | 9.43M | 2.63M | 12.06M |
| Pre-Tax Margin | 13.5% | 13.5% | 20.5% | 4.9% | 18.1% |
| Income Tax Expense | 1.12M | 1.12M | 2.35M | 507K | 3.08M |
| Net Income | 4.57M | 4.57M | 7.07M | 2.13M | 8.98M |
| Net Margin | 10.9% | 10.9% | 15.3% | 4.0% | 13.5% |
| EPS (Basic) | 1.17 | 1.26 | 1.98 | 0.61 | 2.73 |
| EPS (Diluted) | 1.13 | 1.21 | 1.95 | 0.60 | 2.67 |
| Weighted Avg Shares | 3.8M | 3.64M | 3.57M | 3.5M | 3.29M |
| Weighted Avg Shares (Diluted) | 3.94M | 3.76M | 3.64M | 3.57M | 3.36M |
Pro-Dex, Inc.
NASDAQ:PDEX
Intrinsic Alpha fair value
Locked
Current Price
$63.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.